KIRK RANDAL J

KIRK RANDAL J has demonstrated a pronounced selling bias in recent transactions, exclusively trading shares of Precigen Inc. (PGEN) across 32 reported filings. The overwhelming majority of activity—21 of the most recent trades—involves sales, with no recent purchases aside from a single $99,999.90 acquisition on March 10, 2026. The selling has been substantial, totaling $60.6 million in aggregate value, with multiple high-dollar disposals concentrated in late March 2026. Notably, on March 30, 2026, Kirk executed eight separate sales ranging from $78,503.70 to $7.7 million, the latter representing the single largest transaction in the dataset. Earlier disposals on December 22, 2025, followed a similar pattern, with nine sales that day including a $3.99 million transaction and several six-figure dispositions. The transactions suggest a sustained reduction in Kirk’s position in PGEN, with the March 2026 sales alone accounting for over $15.5 million in proceeds. The activity includes a mix of large block sales and smaller disposals, often clustered on single dates, such as the March 30 and December 22 filings. While a minor acquisition in March 2026 via an "A" coded transaction (likely an award or grant) added nominal shares, the overall trend remains decisively bearish. The absence of any offsetting buys—combined with the sheer volume of sales—indicates a deliberate unwinding of exposure to PGEN over time. Kirk’s trading history with the company shows no diversification into other equities, focusing solely on this single biotech holding.